# KEYFORM-008 (NCT05508867)

> A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

No report yet. It can be ordered.

- Drugs tested: favezelimab/pembrolizumab
- Indication: PD-(L)1-refractory relapsed or refractory classical Hodgkin lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05508867
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Hodgkin Lymphoma
- Interventions: favezelimab/pembrolizumab; bendamustine; gemcitabine
- Enrollment: 203
- Primary outcome: Progression Free Survival (PFS) Per Lugano Response Criteria as Assessed by Investigator

## Indexed commentary on KEYFORM-008 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 3
- X threads: 3
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=keyform-008-nct05508867